American Heart Association 2016 Preview

AHA 2016 Rotator
AHA 2016 Rotator
First look at research to be presented at AHA 2016.

The 2016 American Heart Association (AHA) Scientific Sessions will take place from Saturday, November 12 through Wednesday, November 16 in New Orleans, LA.

This year, the AHA will offer 2 new venues—EP (electrophysiology) Central and Interventional Central—for like-minded specialists to meet and network. Non-CME accredited activities will also be offered in these casual settings.

Early Career Day, one of several new AHA programs, will kick off on Saturday, November 12. This event is designed to foster “networking and mentorship between early career members and senior investigators for scientific outreach and career building.”In addition, on Monday, November 13, the Health Tech Summit will examine technology’s role in the treatment and prevention of cardiovascular disease.

Frontiers in Science tracks focus on more specific cardiology subspecialities: Arrhythmia Research Summit (Monday, November 14), Thrombosis Summit (Monday, November 14), Vascular Disease Summit (Monday, November 14), and Stem Cell Summit (Tuesday, November 15).

Finally, download the AHA Mobile Meeting Guide from the App Store or Google Play and access the Interactive Sessions to ask speakers questions on trials or specialty sessions throughout the meeting.

Follow Cardiology Advisor’s coverage of AHA 2016.

AHA 2016 Clinical Trial Highlights

Sunday, November 13

EUCLID – Effects of ticagrelor compared with clopidogrel in patients with peripheral artery disease

PRECISION – Cardiovascular outcomes with celecoxib vs ibuprofen or naproxen

HOPE-3 – The effect of blood pressure and cholesterol lowering on cognition

Monday, November 14

FUTURE – The functional testing underlying coronary revascularization study: a “real world” comparison of fractional flow reserve-guided management vs conventional management in multi vessel coronary artery disease patients

PIONEER AF-PCI – An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention

Tuesday, November 15

ORION 1 – Inhibition of PCSK9 synthesis via RNA interference: 90-day data from Orion-1-a multi-centre phase-2 randomized controlled trial

Wednesday, November 16

ATHENA HF – Aldosterone targeted neurohormonal combined with natriuresis therapy in heart failure

MOMENTUM 3 – Multicenter study of Maglev technology in patients undergoing mechanical circulatory support therapy with HeartMate 3 – primary results of the short term (6 month) cohort


American Heart Association. November 12-16, 2016; New Orleans, LA.
. November 8, 2016.